Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALT NASDAQ:APLS NYSE:BHC NASDAQ:GMTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$4.08+0.7%$5.49$2.90▼$11.16$330.92M0.473.38 million shs3.49 million shsAPLSApellis Pharmaceuticals$19.47-2.8%$18.23$16.10▼$41.94$2.45B0.672.38 million shs1.84 million shsBHCBausch Health Cos$6.31-2.6%$5.60$3.96▼$9.85$2.34B0.412.53 million shs902,877 shsGMTXGemini Therapeutics$57.770.0%$51.05$1.16▼$14.10$2.50B-0.12189,291 shs672,319 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune0.00%-1.45%-39.82%-10.43%-45.53%APLSApellis Pharmaceuticals0.00%+0.15%+9.63%+6.98%-50.70%BHCBausch Health Cos0.00%-1.87%+1.89%+23.12%-17.19%GMTXGemini Therapeutics-0.03%+1.51%+15.33%+37.01%+20.56%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALTAltimmune2.0283 of 5 stars3.41.00.00.02.41.70.6APLSApellis Pharmaceuticals4.3965 of 5 stars4.30.00.04.43.22.50.6BHCBausch Health Cos3.4886 of 5 stars1.94.00.04.00.63.30.6GMTXGemini TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 2.75Moderate Buy$18.20346.08% UpsideAPLSApellis Pharmaceuticals 2.62Moderate Buy$40.00105.44% UpsideBHCBausch Health Cos 1.83Reduce$7.3015.69% UpsideGMTXGemini Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ALT, BHC, GMTX, and APLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/18/2025APLSApellis PharmaceuticalsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$47.00 ➝ $50.007/16/2025APLSApellis PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$23.00 ➝ $24.007/10/2025ALTAltimmuneThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong Sell7/10/2025ALTAltimmuneJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$25.00 ➝ $15.007/2/2025APLSApellis PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$25.00 ➝ $26.006/27/2025ALTAltimmuneWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform6/27/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.006/2/2025APLSApellis PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$26.00 ➝ $29.005/22/2025APLSApellis PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$49.00 ➝ $41.005/14/2025APLSApellis PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$30.00 ➝ $20.005/9/2025APLSApellis PharmaceuticalsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform$75.00 ➝ $52.00(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$20K16,546.44N/AN/A$1.74 per share2.34APLSApellis Pharmaceuticals$781.37M3.13N/AN/A$1.84 per share10.58BHCBausch Health Cos$9.63B0.24$7.70 per share0.82($0.89) per share-7.09GMTXGemini TherapeuticsN/AN/AN/AN/A$2.89 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$95.06M-$1.26N/AN/AN/A-451,200.00%-65.44%-58.43%8/6/2025 (Estimated)APLSApellis Pharmaceuticals-$197.88M-$1.79N/AN/AN/A-28.83%-99.19%-25.35%7/30/2025 (Estimated)BHCBausch Health Cos-$46M-$0.11N/A1.35N/A-0.41%-540.45%5.26%7/30/2025 (Estimated)GMTXGemini Therapeutics-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/ALatest ALT, BHC, GMTX, and APLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ALTAltimmune-$0.3006N/AN/AN/A$0.00 millionN/A8/7/2025Q2 2025APLSApellis Pharmaceuticals-$0.44N/AN/AN/AN/AN/A7/30/2025Q2 2025BHCBausch Health Cos$0.9320N/AN/AN/A$2.47 billionN/A5/13/2025Q1 2025ALTAltimmune-$0.35-$0.26+$0.09-$0.26$0.00 million$0.01 million5/7/2025Q1 2025APLSApellis Pharmaceuticals-$0.36-$0.74-$0.38-$0.74$197.61 million$149.90 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/AAPLSApellis PharmaceuticalsN/AN/AN/AN/AN/ABHCBausch Health CosN/AN/AN/AN/AN/AGMTXGemini TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmuneN/A15.8515.85APLSApellis Pharmaceuticals2.764.083.62BHCBausch Health CosN/A1.350.97GMTXGemini TherapeuticsN/A71.4971.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%APLSApellis Pharmaceuticals96.29%BHCBausch Health Cos78.65%GMTXGemini Therapeutics75.42%Insider OwnershipCompanyInsider OwnershipALTAltimmune4.10%APLSApellis Pharmaceuticals6.50%BHCBausch Health Cos8.05%GMTXGemini Therapeutics12.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune5081.11 million77.78 millionOptionableAPLSApellis Pharmaceuticals770125.68 million117.51 millionOptionableBHCBausch Health Cos20,700370.08 million340.29 millionOptionableGMTXGemini Therapeutics3043.33 million37.74 millionNot OptionableALT, BHC, GMTX, and APLS HeadlinesRecent News About These CompaniesGemini Therapeutics (NASDAQ:GMTX) Stock Price Down 1.9% - Should You Sell?July 15, 2025 | marketbeat.comWhat Is Gemini? Everything You Should Know About Google's AI ToolOctober 17, 2024 | cnet.comGoogle Gemini could soon get a lot more useful on your phoneJuly 31, 2024 | androidpolice.comAGemini Review 2024: Is This Crypto Exchange a Gem for Your Investments?July 22, 2024 | businessinsider.comChatGPT vs. Microsoft Copilot vs. Gemini: Which is the best AI chatbot?May 23, 2024 | zdnet.comZGemini Monthly Horoscope: May 2024May 2, 2024 | pedestrian.tvPGoogle's Gemini AI Will Work On Your Pixel 2 XL—Android 10, 11 Devices Now SupportedApril 28, 2024 | techtimes.comTComparing ChatGPT 3.5, Microsoft Bing, and Google Gemini in diagnosing cases of neuro-ophthalmologyApril 17, 2024 | ophthalmologytimes.comOGoogle's public release of Gemini 1.5 should build trust, Deutsche Bank saysApril 17, 2024 | seekingalpha.comGoogle takes down Gemini AI image generator. Here’s what you need to know.February 26, 2024 | washingtonpost.com‘White privilege is f–king real’: Google Gemini product lead’s old tweets allegedly resurface amid ‘woke’ AI image fiascoFebruary 26, 2024 | nypost.comNGoogle Gemini: Everything you need to know about Google's Answer to ChatGPT – Updated December 2023December 9, 2023 | androidheadlines.comAGemini Review 2023: Pros, Cons and How It ComparesNovember 16, 2023 | nerdwallet.comNYesterday's Gemini HoroscopeOctober 5, 2023 | yourtango.comYGemini Tarot Horoscopes: October 2023October 3, 2023 | glamour.comGYearly Gemini Tarot Card ReadingAugust 28, 2023 | yourtango.comYMove over Bard, Google's next big AI product is coming this fallAugust 19, 2023 | androidauthority.comARadar In Space: The Gemini Rendezvous RadarJuly 27, 2023 | hackaday.comHSun Transit in Gemini- The twins love the Sun’s visitJuly 13, 2023 | prokerala.comPSun Transit in Gemini: Sun with Dual energies?July 5, 2023 | prokerala.comPGemini Allows Withdrawals for Voyager Customers Whose Funds Have Been Trapped since BankruptcyJune 26, 2023 | coinspeaker.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 AI Infrastructure Stocks With Strong Growth, Not HypeBy Chris Markoch | June 26, 2025View 3 AI Infrastructure Stocks With Strong Growth, Not HypeDo They Know Something? Insiders & Congress Buy UnitedHealthBy Brian O'Connell | July 9, 2025View Do They Know Something? Insiders & Congress Buy UnitedHealthForget the Weak Dollar—These 3 Travel Stocks Are Still Taking OffBy Chris Markoch | July 6, 2025View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking OffInsiders Spent Millions on These 3 Stocks Over the Past 2 MonthsBy Leo Miller | July 17, 2025View Insiders Spent Millions on These 3 Stocks Over the Past 2 MonthsWhy Realty Income’s 5.59% Yield Makes It a Must-Buy REITBy Jeffrey Neal Johnson | July 2, 2025View Why Realty Income’s 5.59% Yield Makes It a Must-Buy REITALT, BHC, GMTX, and APLS Company DescriptionsAltimmune NASDAQ:ALT$4.08 +0.03 (+0.74%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$4.10 +0.02 (+0.49%) As of 07/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Apellis Pharmaceuticals NASDAQ:APLS$19.47 -0.57 (-2.84%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$19.97 +0.50 (+2.57%) As of 07/18/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.Bausch Health Cos NYSE:BHC$6.31 -0.17 (-2.62%) Closing price 07/18/2025 03:59 PM EasternExtended Trading$6.42 +0.11 (+1.81%) As of 07/18/2025 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.Gemini Therapeutics NASDAQ:GMTX$57.77 -0.02 (-0.03%) As of 07/18/2025Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
